Positive outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study

Conatus Pharmaceuticals Inc. announces interim results from a clinical trial with CTS-1027

Completion of Versartis Series B Financing

Advent Venture Partners today announced the final close of a $120M (£75M) venture capital fund, to be called Advent Life Sciences

Scrip's Biotech Company of the Year award seeks to acknowledge the vital importance to the industry of biotechnology’s cutting-edge science and entrepreneurial spirit.  This year, from a strong field, the judges chose Algeta as the winner.

Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV).